Pharma Sector

Cupid Ltd shares surged to a fresh 52-week high of ₹214.00, driven by a ₹127.5 crore block deal, an upgraded FY27 revenue outlook, and expectations of record Q1 FY27 revenue. Strong export demand, a long-term global supply agreement, and growth in its domestic consumer wellness business further strengthened investor confidence.

The Indian stock market extended its rally on July 6, 2026, with the Nifty and Sensex closing higher, driven by HDFC Bank's strong Q1 FY27 business update, falling Brent crude prices, sustained FII inflows, and positive global sentiment. Realty, Auto, and Oil & Gas outperformed, while IT, PSU Banks, and Media witnessed profit booking ahead of the earnings season.

Dr. Reddy's Laboratories has expanded its strategic partnership with South Korea's Sam Chun Dang Pharm into advanced liposomal drug formulations. While the collaboration is expected to strengthen its long-term growth pipeline, the stock has also entered a bullish technical phase after breaking above the ₹1,360 resistance level.

The Indian stock market extended its gains on July 2, 2026, with the Nifty closing at 24,175.70 and the Sensex rising 579 points. A strong rebound in IT stocks, lower Brent crude prices, easing US-Iran tensions, a stronger rupee, and lower India VIX boosted investor confidence, while Realty, Auto, Chemicals, Cement, and Consumer Durables also ended in positive territory.

Indian benchmark indices snapped a two-session losing streak on July 1, 2026, as the Nifty 50 climbed above the 24,000 mark and the Sensex gained 444 points. The rally was driven by easing crude oil prices, positive global cues, strong June auto sales, and broad-based buying in Realty, FMCG, Auto, and financial stocks, while IT remained under pressure amid concerns over slowing global technology spending.

Dr. Reddy's Laboratories surged to a new 52-week high as optimism over its biologics pipeline, manageable USFDA observations, new product launches, and strong sector-wide momentum boosted investor confidence. Positive brokerage commentary and expectations of long-term earnings growth further strengthened the stock's rally.

The Indian stock market ended in the red on June 29, 2026, as renewed US-Iran tensions, higher crude oil prices, and profit booking weighed on investor sentiment. Nifty slipped to 23,946 while Sensex lost 372 points. Pharma stocks emerged as the top performers on biosimilar and export optimism, whereas Auto, IT, and Cement sectors witnessed broad-based selling amid cautious global cues.

Bajaj Healthcare share price surged 15% after the company became the first in India to secure the SEC recommendation for Cenobamate tablets. The regulatory milestone is expected to strengthen its CNS portfolio and boost long-term growth prospects.

The Nifty Pharma Index outperformed the broader market by reaching a new 52-week high as pharmaceutical stocks rallied on expanding GLP-1 manufacturing, robust export demand, and positive long-term industry outlook.

Dr. Reddy's Laboratories shares climbed nearly 5% despite the USFDA issuing seven observations at its Bachupally biologics facility. Here's why investors viewed the development positively and what analysts expect next.